Abstract
Malignant pleural mesothelioma (MPM) is an aggressive tumor associated with a general poor prognosis. Recent advances is cancer treatment and the introduction of immunotherapy with checkpoint inhibitors has promoted clinical research with this regards also for MPM. Response assessment based on modified RECIST criteria remains challenging for MPM, however, despite initial promising results, functional imaging with 18F-FDG PET has not found yet a proper place in therapy monitoring of metastatic MPM.
In the following paragraphs, we will illustrate some clinical examples of MPM patients treated with immunotherapy by comparing findings on conventional imaging with metabolic information on PET.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lopci E, Zucali PA, Ceresoli GL, et al. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. Eur J Nucl Med Mol Imaging. 2015;42:667–75.
Novak AK, McDonnel A, Cook A. Immune checkpoint inhibitor for treatment of mesothelioma. Expert Opin Biol Ther. 2019;2:1–10.
van Zandwijk N, Clarke C, Henderson D, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):E254–307.
Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18(5):623–30.
Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7(3):260–70.
Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15:257–60.
Bonomi M, De Filippis C, Lopci E, et al. Clinical staging of malignant pleural mesothelioma: current perspectives. Lung Cancer (Auckl). 2017;8:127–39.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
Zucali PA, Lopci E, Ceresoli GL, et al. Prognostic and predictive role of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. Cancer Med. 2017;6(10):2287–96.
Kanemura S, et al. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma. Eur J Radiol. 2017;86:92–8.
Steinert HC, Santos Dellea MM, Burger C, Stahel R. Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging. Lung Cancer. 2005;49(Suppl 1):S33–5.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Lopci, E., Zucali, P.A. (2020). Malignant Pleural Mesothelioma: 18F-FDG PET/CT for Response Assessment of Malignant Pleural Mesothelioma Following Immunotherapy. In: Lopci, E., Fanti, S. (eds) Atlas of Response to Immunotherapy. Springer, Cham. https://doi.org/10.1007/978-3-030-31113-1_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-31113-1_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-31112-4
Online ISBN: 978-3-030-31113-1
eBook Packages: MedicineMedicine (R0)